

Researcher Speaks Out on Pfizer COVID Vaccine Trial, Calls It a ‘Crazy Mess’

By [Jeremy Loffredo](#)

Global Research, November 16, 2021

[Children's Health Defense](#) 12 November 2021

Region: [USA](#)

Theme: [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

To receive Global Research’s Daily Newsletter (selected articles), [click here](#).

Visit and follow us on Instagram at [@crg_globalresearch](#).

On the latest episode of “The Jimmy Dore Show,” comedian and political commentator Jimmy Dore discussed a report by The BMJ on a whistleblower’s revelations about Pfizer’s Phase 3 COVID vaccine trial.

On the latest episode of “The Jimmy Dore Show,” comedian and political commentator Jimmy Dore discussed the recent [bombshell report](#) in The BMJ on Pfizer’s Phase 3 [COVID vaccine](#) trial.

The BMJ’s report exposed faked data, blind trial failures, delayed follow-ups on serious [adverse reactions](#) and the silencing of researchers who were critical of the trials practices.

A researcher who worked on the trial described the studies to The BMJ as a “crazy mess.”

“[Big Pharma](#) are the biggest liars, scammers and criminals in the country — so you know they had to do some shady stuff with the COVID vaccine and sure enough — they did,” said Dore.

Brook Jackson played a central role in the explosive report. Jackson worked as a regional director at Ventavia Research Group, the outside contractor Pfizer hired to conduct the Phase 3 trial.

The BMJ report mentions how in autumn 2020, [Pfizer CEO Albert Bourla](#) released an [open letter](#) to the billions of people around the world “who were investing their hopes in a safe and effective COVID-19 vaccine to end the pandemic.”

Bourla wrote that the company was “operating at the speed of science.”

“Science says vaccines can’t end the pandemic because they don’t and were [never designed to stop transmission](#),” Dore argued.

The BMJ reported:

“ ... for researchers who were testing Pfizer’s vaccine at several sites in Texas during that autumn, speed may have come at the cost of data integrity and patient safety,” and that “staff who conducted quality control checks were overwhelmed by the volume of problems they were finding.”

Jackson told The BMJ during her two weeks of employment at Ventavia in September 2020, “she repeatedly informed her superiors of poor laboratory management, patient safety concerns and data integrity issues.”

Documents obtained by The BMJ also showed a Ventavia executive was aware of staff members who were “falsifying data.”

The BMJ reported that on Sept. 25, 2020, Jackson called the U.S. Food and Drug Administration to warn about unsound practices in Pfizer’s clinical trial. She then reported her concerns in an email to the agency.

Later that afternoon Ventavia fired Jackson. According to her separation letter, obtained by The BMJ, the Pfizer subcontractor deemed her “not a good fit.”

Jackson told The BMJ it was the first time she had been fired in her 20-year career in clinical research.

Dore said:

“That’s not how science works. You’re supposed to have people documenting adverse reactions so the vaccines can be made safer. If you want the vaccinated to shut up about their adverse reactions that makes you part of a cover-up.”

According to The BMJ, Jackson listed more than a dozen concerns with the trial, including participants not being monitored by clinical staff after injection, lack of timely follow-up of patients who experienced serious adverse events, protocol deviations not being reported, vaccines not being stored at proper temperatures, mislabelled laboratory specimens and the targeting of Ventavia staff for reporting trial issues.

The BMJ also spoke with two former Ventavia employees who agreed to speak with the medical journal anonymously for “fear of reprisal and loss of job prospects in the tightly knit research community.” Both former Ventavia employees confirmed Jackson’s complaint.

One former employee told the journal she had “worked on over four dozen clinical trials in her career, including many large trials” but had never experienced such a “helter-skelter” environment as with Pfizer’s Phase 3 trial.

The BMJ reported that since Ventavia collaborated with Pfizer for its initial Phase 3 trial, Pfizer hired Ventavia as a research subcontractor on other vaccine clinical trials, including the [COVID vaccine for children](#) and young adults, pregnant women and the trials looking at the safety of a booster dose.

“So Pfizer hired them again! Pfizer subcontracts out the risky work so they can have deniability,” Dore said.

John Campbell, Ph.D., discussed The BMJ report in a [recent video](#), asking if the revelations will harm public trust in industry science.

“We should have perfect integrity and transparency all the way through [the scientific process] so the public can completely trust the clinical data ... and this doesn’t help with that,” Campbell said.

Despite the bombshell revelations, the FDA granted [Emergency Use Authorization](#) to the Pfizer COVID vaccine for children ages 5 to 11 years old, while the mainstream corporate press gave the BMJ report little to no coverage.

[Children’s Health Defense](#) asks those concerned about the FDA’s failure to investigate Jackson’s claims to [contact their members of Congress](#).

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Jeremy Loffredo is a freelance reporter for The Defender. His investigative reporting has been featured in The Grayzone and Unlimited Hangout. Jeremy formerly produced news programs at RT America.

Featured image is from CHD

The original source of this article is [Children's Health Defense](#)
Copyright © [Jeremy Loffredo](#), [Children's Health Defense](#), 2021

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Jeremy Loffredo](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long as the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca